Arthur Kuan, CG Oncology CEO
January 3, 2024 02:55 AM EST
Financing

Blad­der can­cer drug­mak­er CG On­col­o­gy files for IPO as biotech mar­ket shows signs of a re­bound

Kyle LaHucik

Senior Reporter

CG On­col­o­gy, a late-stage Cal­i­for­nia biotech de­vel­op­ing a blad­der can­cer ther­a­py, re­vealed its plans to go pub­lic on the Nas­daq in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times